Efficient and low-toxicity Anti-cancer combined drug and pharmaceutical composition

By combining metformin and pyrosimide in a specific proportion, the problem of toxic and side effects of chemotherapy drugs was solved, the anti-cancer activity was significantly enhanced, and the effect of platinum-based chemotherapy was shown in multiple cancer models, while reducing the Toxic side effects provide a highly effective and low-toxic anti-cancer treatment plan.

WO2024244607A1PCT designated stage expired Publication Date: 2024-12-05SICHUAN UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/081582
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-29
Filing Date
2024-03-14
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The existing chemotherapy drugs have obvious toxic and side effects when treating cancer, resulting in a decrease in the quality of life of patients. The anti-cancer effect of metformin and cyperamide alone is not significant enough to be comparable to conventional chemotherapy drugs. It is necessary to develop and enhance the anti-cancer activity of metformin. Combination medication regimen.

Method used

Metformin and ceramide are used in a specific ratio, such as a molar ratio of 250:5-500:5 or a mass ratio of 50:1-150:1, for the treatment of lung, breast or colorectal cancer, significantly enhancing guanidine Tumor-specific killing activity of compounds and reduces toxic side effects.

Benefits of technology

This combination drug regimen significantly inhibits tumor growth in various tumor models, and its toxic side effects are weaker than platinum chemotherapy drugs. It can selectively kill tumor cells without significant impact on normal cells, and its anti-cancer effect is comparable to platinum chemotherapy drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024081582_05122024_PF_FP_ABST
    Figure CN2024081582_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of medicine, and in particular relates to an efficient and low-toxicity anti-cancer combined drug and a pharmaceutical composition. Provided is the use of a guanidine compound combined with piperlongumine in the preparation of an anti-cancer drug. The guanidine compound can be selected from metformin. Compared with a single drug, the combined drug has a better anti-cancer activity. Furthermore, compared with platinum-based chemotherapeutic drugs, the combined drug regimen has the same tumor killing efficacy, but has no significant effect on the body weight, immune system, liver function, kidney function, etc., of mice, indicating that the toxicity and side effects of the combined drug regimen are significantly weaker than those of the platinum-based chemotherapeutic drugs. Therefore, the combined drug scheme has good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

A highly effective and low-toxic anticancer combined drug and drug composition Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular relates to a high-efficiency and low-toxic anticancer combined drug and a pharmaceutical composition. Background Art

[0002] Cancer is a major malignant disease threatening human life and health. In recent years, cancer has become more common among younger patients, with both morbidity and mortality rates rising annually. Currently, chemotherapy remains the primary treatment for cancer. According to statistics, chemotherapy accounts for 73% of the domestic oncology drug market, targeted drugs account for 23%, and immunotherapy drugs account for approximately 4%. However, while chemotherapy is effective, it suffers from significant side effects, often resulting in significant toxicity and side effects. These side effects can severely impact patients' quality of life and can even be a direct cause of death in cancer patients, representing a major bottleneck in cancer chemotherapy. Therefore, the development of new, highly effective, and low-toxic chemotherapy drugs is crucial for improving the quality of life of cancer patients.

[0003] Metformin is a first-line drug for the treatment of type 2 diabetes. A large number of clinical and basic studies have shown that metformin not only has low toxicity and side effects, but also has anti-cancer activity. Studies have shown that metformin can selectively kill various types of tumor cells, but has no significant effect on normal cells. These findings provide a solid theoretical basis for the development of metformin as an effective anti-cancer and low-toxic new drug. However, clinical experiments have shown that the anti-cancer effect of metformin alone is not significant, so the development of metformin enhancers (adjuvants) is an important topic in this field. At present, there have been related studies attempting to enhance the anti-cancer activity of metformin by combining drugs. However, the current combination drug regimens are still not ideal for enhancing the anti-cancer activity of metformin, and cannot make the anti-cancer effect of metformin comparable to that of conventional chemotherapy drugs (such as platinum chemotherapy drugs).

[0004] Piper longum amide is an alkaloid with multiple activities, including anti-inflammatory, antimicrobial, anti-angiogenic, antioxidant, anticancer, and antidiabetic properties. However, the anticancer effects of piper longum amide alone remain limited. Furthermore, there are currently no reports of its anticancer efficacy in combination with metformin.

[0005] In summary, for the purpose of enhancing anti-cancer activity while reducing drug toxicity, there is still a need in the art to develop more combination drug regimens that enhance the anti-cancer activity of metformin.

[0006] Summary of the Invention

[0007] In response to the problems of the prior art, the present invention provides a highly effective and low-toxic anticancer combination drug and pharmaceutical composition, the purpose of which is to enhance the anticancer activity of guanidine compounds such as metformin through combined use.

[0008] Use of guanidine compounds combined with piperlongum amide in the preparation of anticancer drugs.

[0009] Preferably, the molar ratio of the guanidine compound to the piper longum amide is 250:5-500:5 or the mass ratio is 50:1-150:1. Preferably, the molar ratio of the guanidine compound to the piper longum amide is 250:5 or the mass ratio is 100:1.

[0010] Preferably, the guanidine compound is selected from metformin.

[0011] Preferably, the anticancer drug is used to treat lung cancer, breast cancer or colorectal cancer.

[0012] The present invention also provides a combined drug for anticancer, wherein the combined drug is a guanidine compound and piperlongum amide administered separately or simultaneously.

[0013] Preferably, the molar ratio of the guanidine compound to the piper longum amide is 250:5-500:5 or the mass ratio is 50:1-150:1. Preferably, the molar ratio of the guanidine compound to the piper longum amide is 250:5 or the mass ratio is 100:1.

[0014] Preferably, the guanidine compound is selected from metformin.

[0015] Preferably, the combination drug is used to treat lung cancer, breast cancer or colorectal cancer.

[0016] The present invention also provides a pharmaceutical composition, which is prepared by using guanidine compounds and piperlongum amide as active ingredients and adding pharmaceutically acceptable excipients or auxiliary ingredients.

[0017] Preferably, the molar ratio of the guanidine compound to the piper longum amide is 250:5-500:5 or the mass ratio is 50:1-150:1. Preferably, the molar ratio of the guanidine compound to the piper longum amide is 250:5 or the mass ratio is 100:1.

[0018] Preferably, the guanidine compound is selected from metformin.

[0019] Preferably, the pharmaceutical composition is used to treat lung cancer, breast cancer or colorectal cancer.

[0020] The present invention combines longanamide with guanidine compounds (such as metformin), which can significantly enhance the tumor-specific killing activity of guanidine compounds. This effectiveness and specificity have been repeatedly verified in a variety of tumor models, including lung cancer / breast cancer / colorectal cancer PDX models (Patient-derived xenograft models) and MMTV-PyMT-induced spontaneous breast cancer mouse models. More importantly, compared with platinum-based chemotherapy drugs, this combination therapy has the same tumor killing efficacy, but has no significant effect on mouse body weight, immune system, liver function, kidney function, etc., indicating that its toxic side effects are significantly weaker than platinum-based chemotherapy drugs. Therefore, the combined drug method of the present invention has a good application prospect.

[0021] It is important to note that the experimental examples of the present invention include in vitro cell experiments, demonstrating that the co-treatment of tumor cells with piperlongamide and guanidine compounds demonstrated a good selective killing effect on tumor cells. Therefore, when used to treat cancer, the piperlongamide and guanidine compounds of the present invention can be used in combination with existing pharmaceutical preparations or as a combined formulation for administration.

[0022] Obviously, based on the above contents of the present invention, according to common technical knowledge and customary means in this field, various other modifications, replacements or changes can be made without departing from the above basic technical ideas of the present invention.

[0023] The following further describes the above content of the present invention in detail through specific embodiments in the form of examples. However, this should not be construed as limiting the scope of the above subject matter of the present invention to the following examples. All technologies implemented based on the above content of the present invention fall within the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 shows experimental results demonstrating the key role of reactive oxygen species in the selective killing of tumor cells by metformin. The indicated cells were treated with 250 μM metformin alone or in combination with 5 μM piperlongumine (piper) for 48 hours, and cell viability was assessed using trypan blue staining (A) or PI staining (B).

[0025] Figure 2 shows the experimental results showing that the combination of metformin and piperlongumide significantly inhibits the growth of spontaneous mammary tumors induced by MMTV-PyMT in mice. (A) Tumor growth in female MMTV-PyMT mice at 95 days of age. (B) Dosage pattern diagram. According to the dosing pattern in B, 49-day-old female MMTV-PyMT-positive mice (4 per group) were treated intraperitoneally with 100 mg / kg of metformin and 1 mg / kg of piperlongumide, either alone or in combination, for 46 consecutive days. At 95 days of age, tumor size (C), tumor number (D), and tumor weight (E) were measured.

[0026] Figure 3 shows the experimental results that the combination of metformin and piperlongum amide significantly inhibited the growth of breast cancer and colorectal cancer xenografts in mice and prolonged the survival of mice. 5 4T-1 cells (A and B) or 5*10 5 CT-26 cells (C and D) were inoculated subcutaneously in the right neck of 6-week-old female Balb / c mice. On the third day after cell inoculation, 100 mg / kg of metformin and 1 mg / kg of piperlongum (MP) were intraperitoneally injected daily, while the control group was injected with an equal volume of PBS (Ctrl). One group of mice received the drug for 18 consecutive days, and the tumors were removed and weighed (A and C). Another group of mice continued to receive the drug until the tumors grew to 1500 mm. 3 The mice were deemed to have died ethically, and survival curves were drawn (C and D).

[0027] Figure 4 shows the experimental results that the combination of metformin and piperlongum amide significantly inhibited the growth of lung cancer, breast cancer and colorectal cancer PDX (Patient-derived xenograft) tumors. 3 PDX tumors were cut into small pieces and inoculated subcutaneously into the right neck of NSG mice. When PDX tumors grew to 15-20 mm, the experimental group received an intraperitoneal injection of MP (100 mg / kg metformin and 1 mg / kg piperlongum amide daily), while the control group received an equal volume of PBS (Ctrl). Tumor growth was dynamically monitored with a vernier caliper on days 0, 4, 8, 12, 16, 18, and 24 after injection. On day 24, the tumors were removed, photographed, and weighed.

[0028] Figure 5 shows the experimental results that the combination of metformin and piperlongum amide has the same tumor killing effect as platinum chemotherapy drugs. (A) Dosage pattern diagram. 5 4T-1 cells (B and C) or 5*10 5LLC cells (D and E) were inoculated subcutaneously into the right neck of female Balb / c mice (4T-1) or C57BL / 6 mice (LLC). On the third day after cell inoculation, the mice were divided equally into four groups (ctrl control group, MP group, Cis group, and Car group). The MP group was intraperitoneally injected with 100 mg / kg of metformin and 1 mg / kg of piperidine every day; the Cis group was intraperitoneally injected with 5 mg / kg of cisplatin once every 5 days; the Car group was intraperitoneally injected with 50 mg / kg of carboplatin once every 5 days; and the ctrl control group was injected with an equal volume of PBS every day. On the 15th day of administration, the tumors were removed and the tumor weight was measured (BE).

[0029] Figure 6 shows the experimental results showing that the combination of metformin and piperlongumide had no significant effect on mouse body weight, immune system, liver and kidney function. The effects of MP, cisplatin, and carboplatin on mouse body weight, spleen weight, and peripheral blood leukocyte count were examined according to the dosing pattern shown in Figure 6 (A and B). Female FVB mice were treated with 100 mg / kg metformin and 1 mg / kg piperlongumide daily (intraperitoneal injection) for 35 days. The control group was injected with an equal amount of PBS (Ctrl). On day 20 of treatment, the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, and cystatin C (Cys-C) in the mouse peripheral blood were measured (C and D).

[0030] Figure 7 shows experimental results showing that platinum-based drugs indiscriminately kill normal and tumor cells, but their combination with metformin and piperlongum amide selectively kills tumor cells. (A-H) Cells were treated with cisplatin or carboplatin at the indicated concentrations, and cell survival was assessed using trypan blue staining. (I-J) Cells were treated with 250 μM metformin alone or in combination with 5 μM piperlongum amide, and cell survival was assessed using trypan blue staining. *** indicates p < 0.0001. DETAILED DESCRIPTION

[0031] In the following examples and experimental examples, the reagents and raw materials used are all commercially available.

[0032] Example 1 Combination drug for anticancer

[0033] This embodiment provides an anticancer combination drug, which is an injection containing 250 μM metformin and 5 μM piperlongum amide.

[0034] Example 2 Combination Drugs for Anticancer

[0035] This embodiment provides an anticancer combination drug, which is an injection containing 500 μM metformin and 5 μM piperlongum amide.

[0036] Example 3 Combination Drugs for Anticancer

[0037] This embodiment provides an anticancer combination drug, which is a tablet containing 100 mg of metformin and 1 mg of piperlongum amide.

[0038] Example 4 Composition for Anticancer

[0039] This embodiment provides an anticancer composition, which is an injection containing 250 μM metformin and 5 μM piperlongum amide.

[0040] Example 5 Composition for Anticancer

[0041] This embodiment provides an anticancer composition, which is an injection containing 500 μM metformin and 5 μM piperlongum amide.

[0042] Example 6 Composition for Anticancer

[0043] This embodiment provides an anticancer combination drug, which is a tablet containing 80 mg of metformin and 1 mg of piperlongum amide.

[0044] Example 7 Composition for Anticancer

[0045] This embodiment provides an anticancer combination drug, which is a tablet containing 120 mg of metformin and 1 mg of piperlongum amide.

[0046] The technical solution of the present invention is further illustrated by experiments below. In the following experimental examples, the combined medication regimen of metformin and piperlongumine is referred to as MP.

[0047] Experimental Example 1 Anticancer Activity of Metformin and Its Combination with Piperglucoside

[0048] 1. Experimental Methods

[0049] 1. Cell viability assay

[0050] The cultured tumor cells were digested with trypsin and collected; the cells were washed twice with PBS and then counted to a cell concentration of 1×10 5 / 100L; take 2×10 5 Tumor cells were placed in 12-well plates and cultured overnight in a 37°C incubator. Cells were treated with 250 μM metformin alone or in combination with 5 μM piperlongumine (piper) for 48 hours. All cells (including suspended cells) were collected, dead cells were stained with trypan blue or PI (Propidium Iodide), and cell death rate was detected using a LUNA-FLTM automated cell counter.

[0051] 2. Detection of the anticancer activity of MP using the MMTV-PyMT-induced spontaneous breast cancer model in mice

[0052] 49-day-old female mice positive for MMTV-PyMT were divided equally into two groups (control group and MP group), with four mice in each group. Mice in the experimental group received intraperitoneal injections of MP (100 mg / kg metformin and 1 mg / kg piperlongumamide daily), while mice in the control group received an equal volume of PBS (control group). On day 46 after injection, tumors were removed, photographed, and tumor number and weight were counted.

[0053] 3. Using the CDX (Cell-derived xenograft) model to investigate the anticancer activity of MP

[0054] 1*10 5 4T-1 cells or 5*10 5 CT-26 cells were inoculated subcutaneously in the right neck of 6-week-old female Balb / c mice. On the third day after cell inoculation, 100 mg / kg of metformin and 1 mg / kg of piperlongum (MP) were intraperitoneally injected daily. A control group was injected with an equal volume of PBS (Ctrl). One group of mice received the drug for 18 consecutive days, at which time the tumors were removed and weighed. The other group of mice continued to receive the drug until the tumors grew to 1500 mm. 3 The mice were deemed to have died ethically, and survival curves were drawn.

[0055] 4. Detecting the anticancer activity of MP using lung cancer, breast cancer, and colorectal cancer PDX (Patient-derived xenograft) models

[0056] Fresh human lung / breast / colorectal tumor tissues were cut into 1-3 mm3 pieces (F0 generation) and inoculated into the right neck subcutaneous tissue of female severely immunodeficient mice (NSG mice) (F1 generation); when the tumor volume grew to 400-600 mm 3 , remove the tumor and re-cut it into 1-3mm 3 The tumor was re-inoculated into the subcutaneous tissue of the right neck of NSG mice (F2 generation); and then the tumor was grown to 400-600 mm 3 Tumor tissue was stored in liquid nitrogen or inoculated subcutaneously into the right neck of new NSG mice (generations F3-F6) for efficacy evaluation. Tumor tissue was retained from each generation to verify the molecular and histomorphological consistency of tumor samples from each generation.

[0057] Prepare 16 6-week-old female NSG mice and divide them equally into control group and experimental group (8 mice in each group); cut each PDX tumor of F3 generation into 1-3 mm 3Small pieces were inoculated into the subcutaneous tissue of the right neck of NSG mice; when the PDX tumor grew to 15-20 mm 3 Mice in the experimental group were intraperitoneally injected with MP (100 mg / kg of metformin and 1 mg / kg of piperlongum amide, daily), while mice in the control group were injected with an equal volume of PBS (Ctrl). Tumor growth was dynamically monitored with a vernier caliper on days 0, 4, 8, 12, 16, 18, and 24 after injection. On day 24, the tumor was removed, photographed, and weighed.

[0058] 5. Comparison of the tumor-killing effects of MP and platinum chemotherapy drugs using the CDX model

[0059] 1*10 5 4T-1 cells or 5*10 5 LLC cells were inoculated subcutaneously into the right neck of female Balb / c mice (4T-1) or C57BL / 6 mice (LLC). Three days after cell inoculation, the mice were divided equally into four groups (control, MP, Cis, and Car, with six mice in each group). The MP group received daily intraperitoneal injections of 100 mg / kg metformin and 1 mg / kg piperlongumamide; the Cis group received intraperitoneal injections of 5 mg / kg cisplatin every five days; the Car group received intraperitoneal injections of 50 mg / kg carboplatin every five days; and the control control group received an equal volume of PBS daily. On the 15th day of administration, tumors were removed and tumor weights were measured.

[0060] 2. Experimental Results

[0061] 1. Anticancer activity of metformin alone or in combination with piperlongumamide

[0062] First, we examined the effect of piperlongumine (piper) on the anticancer activity of low-dose metformin (250 μM). As shown in Figures 1A and 1B, the combined use of metformin and piperlongumine significantly inhibited the survival of various tumor cells compared to low-dose metformin or piperlongumine alone.

[0063] 2. The combination of metformin and piperlongum amide significantly inhibited the growth of spontaneous mammary tumors in mice induced by MMTV-PyMT

[0064] These studies demonstrate that piperlongamide plays a key role in the anticancer activity of metformin. Therefore, the combination of metformin and piperlongamide may represent a novel tumor treatment strategy. To validate the in vivo anti-tumor activity of the combined metformin and piperlongamide approach, we first selected the MMTV-PyMT mouse model of spontaneous mammary tumors (in this model, the Polyoma virus middle T antigen / PyMT is specifically expressed in mammary cells, leading to abnormal mammary cell proliferation; mice develop primary mammary tumors at week 5 and significant lung metastases at week 12). As shown in Figure 2A, MMTV-PyMT mice developed prominent tumors around the mammary gland at 95 days of age. Based on this, in this study, mice were intraperitoneally injected with 100 mg / kg of metformin and 1 mg / kg of piperlongamide, either alone or in combination, at day 49 for 46 consecutive days. Tumor size and number were observed at day 95 (Figure 2B). As shown in Figures 2C-E, metformin or piperlongamide alone had no significant effect on tumor growth in mice, but the combined use of metformin and piperlongamide significantly inhibited breast tumor growth in mice. These results suggest that the combined use of metformin and piperlongamide is a potential new strategy for tumor treatment.

[0065] 3. The combination of metformin and piperlongum amide significantly inhibited the growth of breast cancer and colorectal cancer xenografts in mice and prolonged the survival of mice

[0066] Next, the anticancer activity of the combined metformin and piperlongumamide was tested in mouse xenograft tumor models mediated by mouse breast cancer cell line 4T-1 and mouse colorectal cancer cell line CT-26. As shown in Figure 3, MP significantly inhibited tumor growth in mice and significantly prolonged the survival of tumor-bearing mice.

[0067] 4. Combination of metformin and piperlongum amide significantly inhibited tumor growth in lung cancer / breast cancer / colorectal cancer PDX mouse models

[0068] Furthermore, this experimental example tested the inhibitory effects of metformin and piperlongum on tumor growth in patient-derived xenograft models. In this experimental example, human colorectal cancer (Colon cancer), lung cancer (Lung Cancer), and triple-negative breast cancer (TNBC) PDX models were successfully established. As shown in Figure 4, compared with the control group (Ctrl), MP significantly inhibited tumor growth in colorectal cancer (Figures 4A-B), lung cancer (Figures 4C-D), and triple-negative breast cancer (Figures 4E-F) PDX models.

[0069] 5. Combination of metformin and piperlongum amide has the same tumor killing effect as platinum chemotherapy drugs

[0070] Currently, chemotherapy remains the primary treatment for cancer. Platinum-based drugs are one of the main types of chemotherapeutic agents. Next, this study compared the inhibitory effects of MP with platinum-based drugs (cisplatin and carboplatin) on tumor growth in xenograft models mediated by mouse breast cancer 4T-1 cells and mouse lung cancer LLC cells. As shown in Figure 5, MP exhibited comparable tumor-suppressing effects as cisplatin or carboplatin in both tumor models.

[0071] 6. The combination of metformin and piperlongum amide had no significant effect on the body weight, immune system, liver and kidney function of mice

[0072] Next, this experimental example compared the effects of MP and platinum drugs (cisplatin and carboplatin) on normal physiological parameters in mice using xenograft models mediated by mouse breast cancer cells 4T-1 and mouse lung cancer cells LLC. As shown in Figures 6A-B, cisplatin and carboplatin significantly inhibited mouse body weight, spleen weight, and peripheral blood leukocyte count, while MP had no significant effect on these parameters. In addition, MP had no significant effect on the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, and cystatin C (Cys-C) in the mouse peripheral blood, indicating that MP has no toxic side effects on mouse liver and kidney function.

[0073] 7. Platinum drugs kill normal and tumor cells indiscriminately, but combined with metformin and piperlongum amide, they can selectively kill tumor cells.

[0074] The experiment found that 40μM cisplatin and 320μM carboplatin could kill 80% of tumor cells (Figure 7A-F), but they also indifferently inhibited the survival of 80% of normal cells (Figure 7G-H). The combination of 250μM metformin and 5μM piperidine also killed 80% of tumor cells (Figure 7I), but had no significant effect on normal cells (Figure 7I). The results showed that on the basis of the equivalent killing of tumor cells by MP and platinum drugs, platinum drugs indifferently inhibited the survival of normal cells, while MP had no significant effect on the survival of normal cells. This result provides a cellular basis for the high efficiency and low toxicity of MP.

[0075] In summary, the experimental results of this example demonstrate that the combination of metformin and piperlongamide significantly enhances anticancer activity compared to either metformin or piperlongamide alone, and that MP's anticancer activity is comparable to that of platinum-based chemotherapy drugs. Furthermore, compared to platinum-based chemotherapy drugs, while maintaining comparable anticancer activity, MP exhibits no toxic side effects and selectively kills tumor cells.

[0076] Therefore, the combined drug regimen of the present invention has good application prospects.

Claims

1. Use of guanidine compounds combined with piperlongum amide in the preparation of anticancer drugs.

2. The use according to claim 1, characterized in that: The usage ratio of the guanidine compound to piperlongum amide is: a molar ratio of 250:5-500:5 or a mass ratio of 50:1-150:

1.

3. The use according to claim 1, characterized in that: The guanidine compound is selected from metformin.

4. The use according to claim 1, characterized in that: The anticancer drug is used to treat lung cancer, breast cancer or colorectal cancer.

5. A combined drug for anticancer use, characterized in that: The combined drug is a guanidine compound and piperlongum amide administered separately or simultaneously.

6. The combined drug according to claim 5, characterized in that: The usage ratio of the guanidine compound to piperlongum amide is: a molar ratio of 250:5-500:5 or a mass ratio of 50:1-150:

1.

7. The combined drug according to claim 5, characterized in that: The guanidine compound is selected from metformin.

8. The combined drug according to claim 5, characterized in that: The combined drug is used for treating lung cancer, breast cancer or colorectal cancer.

9. A pharmaceutical composition, characterized in that: The invention is prepared by taking guanidine compounds and piperlongum amide as active ingredients and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.

10. The pharmaceutical composition according to claim 9, characterized in that: The usage ratio of the guanidine compound to piperlongum amide is: a molar ratio of 250:5-500:5 or a mass ratio of 50:1-150:

1.

11. The pharmaceutical composition according to claim 9, characterized in that: The guanidine compound is selected from metformin.

12. The pharmaceutical composition according to claim 9, characterized in that: The pharmaceutical composition is used for treating lung cancer, breast cancer or colorectal cancer.

Citation Information

Patent Citations

  • Applications of piperlongumine in preparation of anti-neoplasm metastasis drugs

    CN104415035A

  • Combined medicine for treating cancer and application thereof

    CN110665007A

  • Methods and compositions for treating cancer

    US10888569B1

  • Long Pepper Extract an Effective Anticancer Treatment

    US20160143979A1